Introduction {#s1}
============

Patients with type 2 diabetes are at increased risk for dementia and cognitive decline ([@B1],[@B2]). Neuroimaging is useful for determining structural and functional biomarkers that may predict future cognitive impairment, thereby elucidating the mechanisms involved in cognitive decline and informing strategies to target vulnerable brain regions ([@B3],[@B4]).

Recent research has focused on the default mode network (DMN), a set of medial prefrontal and temporo-parietal regions that are most active at rest and deactivated during cognitive tasks. The DMN exhibits both reduced functional connectivity ([@B5]) and impaired task-induced deactivation ([@B6]) in Alzheimer disease (AD) and mild cognitive impairment (MCI). These changes have been observed before atrophy and cognitive decline and are concurrent with other signals that are known predictors of cognitive decline ([@B6]). The DMN also has high metabolic activity, making it susceptible to the effects of type 2 diabetes and hypo- or hyperglycemia ([@B7]). Patients with type 2 diabetes show impaired functional connectivity ([@B8]) and abnormal glucose metabolism ([@B9]) in the DMN, but no study has investigated whether they show reduced ability to suppress DMN activity during a cognitive task.

This study investigates brain activity patterns during encoding and recognition tasks using functional magnetic resonance imaging (fMRI) in middle-aged type 2 diabetic patients, focusing on the DMN. These regions, in particular the prefrontal cortex, are involved in both encoding ([@B10]) and recognition ([@B11]). Since elderly patients with type 2 diabetes often demonstrate cognitive impairments ([@B12]), it is important to identify task-related functional alterations that may precede cognitive decline so that preventative therapies can be introduced in middle age.

Research Design and Methods {#s2}
===========================

Subjects {#s3}
--------

We studied 22 patients with type 2 diabetes and 29 nondiabetic healthy control subjects between the ages of 45 and 65 years ([Table 1](#T1){ref-type="table"}). Patients were group matched on education, IQ, sex, and BMI, and we accounted for a group age difference in our analyses.

###### 

Demographics, clinical variables, and cognitive scores

                                                             Type 2 diabetic patients (*N* = 22)   Control subjects (*N* = 29)                  
  ---------------------------------------------------------- ------------------------------------- ----------------------------- ------- ------ --------
  Age, years                                                 56.0                                  5.5                           52.7    5.5    0.03
  Education, years                                           14.9                                  2.5                           16.0    2.5    0.14
  Current HbA~1c~, %                                         7.8                                   2.4                           5.6     0.3    \<0.01
  Current HbA~1c~, mmol/mol                                  62                                    26                            38      3      \<0.01
  Lifetime average HbA~1c~, %                                7.7                                   2.1                                          
  Lifetime average HbA~1c~, mmol/mol                         61                                    23                                           
  Fasting plasma glucose, mmol/L                             8.5                                   5.6                           4.5     0.4    \<0.01
  Fasting serum insulin, pmol/L                              84.7                                  66.6                          54.2    48.6   0.03
  Prescan PG, mmol/L                                         10.2                                  4.4                                          
  HOMA-IR                                                    5.4[\*](#t2n1){ref-type="table-fn"}   5.8                           1.6     1.4    \<0.01
  Diabetes duration, years                                   9.0                                   6.3                                          
  BMI, kg/m^2^                                               30.1                                  4.8                           28.6    4.8    0.20
  Systolic blood pressure, mmHg                              127.9                                 13.5                          118.7   13.6   0.02
  Diastolic blood pressure, mmHg                             72.4                                  10.1                          72.8    10.3   0.94
  Serum creatinine, mmol/L                                   0.04                                  0.01                          0.04    0.01   0.19
  Total cholesterol, mmol/L                                  11.1                                  2.5                           10.4    1.7    0.39
  Triglycerides, mmol/L                                      8.4                                   9.3                           5.6     3.8    0.03
  HDL cholesterol, mmol/L                                    3.2                                   1.1                           2.9     0.9    0.40
  LDL cholesterol, mmol/L                                    6.2                                   1.5                           6.1     1.5    0.96
  Hamilton Depression Rating Score                           4.9                                   4.5                           3.4     3.8    0.18
  WASI full-scale IQ                                         108.1                                 14.2                          112.7   12.3   0.21
  WASI vocabulary score                                      55.4                                  8.8                           57.5    9.4    0.41
  DKEFS verbal fluency, scaled score                         11.3                                  4.4                           12.5    3.3    0.39
  DKEFS trail-making number-letter switching, scaled score   9.4                                   3.8                           10.3    3.3    0.35
  RAVLT immediate-recall T score                             49.8                                  11.8                          50.2    13.9   0.95
  RAVLT delayed-recall T score                               49.9                                  8.4                           48.4    12.2   0.82
  WMS letter-number sequencing score                         11.3                                  3.5                           12.5    2.3    0.17
  Grooved Pegboard, dominant hand, time in seconds           88.6                                  20.3                          81.9    10.8   0.51
  Recognition fMRI task performance percentage correct       73.6                                  17.0                          68.7    15.0   0.25
                                                             *N*                                   \%                            *N*     \%     *P*
  Female/male (% female)                                     11/11                                 50                            10/19   34     0.27
  Race/ethnicity                                                                                                                                0.27
   African American                                          2                                     9                             6       21     
   Asian                                                     2                                     9                             1       3      
   Caucasian                                                 14                                    64                            21      72     
   Hispanic                                                  2                                     9                             0       0      
   More than one                                             2                                     9                             1       3      
  APOE4 allele                                               3                                     14                            6       21     0.71
  Blood pressure--lowering medications                       7                                     32                            4       14     0.17
  Cholesterol-lowering medications                           5                                     23                            1       3      0.07
  History of smoking                                         9                                     41                            13      45     0.78
  Retinopathy                                                1                                     5                                            
  Neuropathy                                                 2                                     9                                            
  Nephropathy                                                0                                     0                                            

DKEFS, Delis-Kaplan Executive Function System; RAVLT, Rey Auditory Verbal Learning Test; WASI, Wechsler Abbreviated Scale of Intelligence; WMS, Wechsler Memory Scale-III.

\*Noninsulin users only, *N* = 12.

We gathered medical history and current medications from medical records and questionnaires. Since insulin resistance was of interest, we excluded patients treated with the insulin-sensitizing medications metformin or thiazolidinediones. Eligible patients were on stable therapy with diet, insulin, or oral medications. After approval from the institutional review boards of the Joslin Diabetes Center and Beth Israel Deaconess Medical Center (where the MRI was performed), subjects provided informed consent and information about psychiatric history, handedness, medical history, current medications, height, and weight. Exclusionary criteria were as follows: *1*) stroke or myocardial infarction; *2*) unstable or current episode of a DSM-IV Axis I disorder; *3*) sleep, eating, or learning disorder; *4*) sensorimotor handicap, central nervous system disorder, or illness affecting neurological function; *5*) history of substance abuse (including alcohol and excluding nicotine); *6*) left-handedness ([@B13]); *7*) contraindications to magnetic resonance imaging (MRI); and *8*) BMI \>40 kg/m^2^.

Screening Visit {#s4}
---------------

Participants provided a blood sample after an 8-h fast to assess creatinine, HbA~1c~, lipids, serum insulin, plasma glucose (PG), and apolipoprotein E (APOE) allele status, as the ε4 isoform confers risk for AD. Medication administration occurred after baseline blood draws. Nondiabetic participants drank 75 g flavored dextrose, and blood samples were taken intravenously at 30, 60, and 120 min postingestion to measure PG and serum insulin to calculate insulin resistance using the homeostasis model assessment of insulin resistance (HOMA-IR). HOMA-IR was not assessed for insulin-treated type 2 diabetic patients because it would not reflect their natural insulin sensitivity. Participants also answered demographic and socioeconomic questionnaires, completed a fitness assessment, and underwent cognitive testing.

Cognitive Assessment {#s5}
--------------------

We measured executive function (Delis-Kaplan Executive Function System), memory (Rey Auditory Verbal Learning Test; Wechsler Memory Scale-III), intelligence (Wechsler Abbreviated Scale of Intelligence), and psychomotor speed (Grooved Pegboard Test) as described previously ([@B8]) ([Table 1](#T1){ref-type="table"}).

MRI Acquisition {#s6}
---------------

PG measures were taken prior to magnetic resonance scanning for diabetic participants. Treatment was provided for PG \<4.4 mmol/L or \>16.6 mmol/L (*N* = 2). Images were collected on a GE Healthcare Signa HDxt 3.0T system (Milwaukee, WI). Participants underwent screening for metal objects, pacemakers, pregnancy, and claustrophobia. Of the 57 eligible participants, 6 were excluded owing to head movement during scanning. Exclusion criteria included translations or rotations of \>3 mm in *x*, *y*, or *z* directions.

Functional Images {#s7}
-----------------

Functional images were collected in the axial plane using a gradient echo planar imaging sequence sensitive to blood oxygen level dependent (BOLD) contrast (repetition time/echo time = 2,000/25 ms; flip angle = 90°; slice thickness = 4 mm; two-dimensional in-plane: field of view = 24 × 24 cm^2^, matrix size = 64 × 64; voxel size = 3.75 × 3.75 × 4 mm^3^).

fMRI Cognitive Task {#s8}
-------------------

fMRI scans were collected during both the encoding and recognition tasks (5 min each). Stimuli were presented using Presentation software (Neurobehavioral Systems, Albany, CA), projected on a screen visible via mirror attached to head coil. Trials were synchronized with the acquisition sequence. Responses were collected using a four-button Lumina fiberoptic response pad (<http://www.cedrus.com/lumina>), connected to a personal computer via optical cable interface.

During encoding, subjects saw green and red images and concentrated on the pairing of the object and its color ([@B14]). During recognition, subjects indicated via button press the original color of the same images now presented in black and white. Control and rest blocks were used during both tasks. Block order was randomized, and images were presented for 3,000 ms followed by a fixation cross for 1,000 ms.

Image Processing {#s9}
----------------

fMRI image analyses and processing were completed using the Functional MRI of the Brain Software Library (FSL) software package version 5.0.4. Images were registered to the standard MNI152 brain (Montreal Neurological Institute). The first two volumes were deleted for T1 equilibration. Motion and slice time correction, brain extraction, spatial smoothing with Gaussian filter of 6 mm full width at half maximum, linear trend removal, and a temporal high-pass filter with cutoff of 120 s were performed. All image analysts were blind to group status.

Data Analysis {#s10}
-------------

Demographic, clinical, and cognitive data were compared between groups using Mann-Whitney *U* tests for all continuous variables and Fisher exact tests for all categorical variables except sex, for which a Pearson χ^2^ test was used.

For examination of regional brain activation in response to the encoding and recognition tasks, a general linear model was used to compute statistical parametric maps by random-effects multiple regression analysis for each task. Model predictors for BOLD signal time courses were constructed using the boxcar time courses for the task stimulus paradigm convolved with a γ function to account for hemodynamic response. The model for the baseline rest condition predictor was a constant function. Cerebral BOLD activations and deactivations were determined by applying relevant contrast *F* tests to β-weights for each voxel position ([Fig. 1](#F1){ref-type="fig"}). Activations were computed by contrasting the encoding and recognition blocks to their respective control blocks, and deactivations were compared with their respective rest periods.

![Regions activated (red) and deactivated (blue) during the encoding (*A*) and recognition (*B*) tasks in control subjects (CO) and type 2 diabetic patients (T2DM). Group differences between control subjects and diabetic patients and between diabetic patients with PG ≥11 mmol/L and \<11 mmol/L. Age was controlled for in these analyses. See [Table 2](#T2){ref-type="table"} for region lists. Statistical parametric brain activation maps within and between groups were computed using one-sample *t* tests for within-group and unpaired two-sample *t* tests for between-group analyses with a significance threshold of *P* \< 0.05 (corrected). A *z* statistic threshold value of 2.3 was applied using the standard cluster-based thresholding Gaussian Random Field theory for inference provided by FSL ([@B25]).](3112fig1){#F1}

To verify hippocampal activation, we created binary masks of the left and right hippocampus using the Harvard-Oxford Subcortical Structural Atlas thresholded at the 50% probability level. We extracted average- and maximal-activation *z* scores from the hippocampal regions of interest (ROI) using FSL's fslstats tool.

We investigated the effects of the AD risk allele APOE4 ([@B15],[@B16]), current and lifetime average HbA~1c~ (calculated by averaging 4-year means), and HOMA-IR on BOLD activation and deactivation within each group by performing separate mixed-effects general linear model group analyses in FSL. We also compared BOLD activation and deactivation between diabetic patients with prescan PG ≥11 mmol/L and \<11 mmol/L to determine the effects of acute hyperglycemia ([Fig. 1](#F1){ref-type="fig"}). We then performed anatomical ROI analyses using the Harvard-Oxford atlas and FSL's Featquery tool to examine Spearman correlations between prescan PG and deactivation in DMN regions.

All data are presented as mean ± SD, and statistical tests were conducted using a two-sided α-level of 0.05 with SPSS Statistical Software, version 19.

Results {#s11}
=======

Demographics and Clinical Variables {#s12}
-----------------------------------

[Table 1](#T1){ref-type="table"} shows demographic and clinical data for diabetic patients and healthy control subjects.

Cognitive Performance {#s13}
---------------------

There were no significant differences between groups on any cognitive tests, including vocabulary (a measure of premorbid IQ \[[@B17]\]) and the fMRI task ([Table 1](#T1){ref-type="table"}).

Functional Imaging {#s14}
------------------

For both tasks, [Fig. 1](#F1){ref-type="fig"} shows activated and deactivated regions and [Table 2](#T2){ref-type="table"} lists local maxima. [Table 3](#T3){ref-type="table"} lists the effects of covariates. APOE4 was evaluated in each group separately, HOMA-IR only in control subjects, and current and lifetime average HbA~1c~ only in diabetic patients.

###### 

Local maxima of activation and deactivation during encoding and recognition tasks in control subjects and diabetic patients; group differences in activation and deactivation between control subjects and diabetic patients and between diabetic patients with prescan plasma glucose ≥11 mmol/L and \<11 mmol/L

                                                                                               MNI coordinates               
  --------------------------------------------------------- ----- ---------------------------- ----------------- ----- ----- ------
  Encoding                                                                                                                   
   Activation                                                                                                                
    Control                                                                                                                  
     Cerebellum                                             L+R   Cerebellum                   −26               −59   −17   8.77
     Frontal                                                L     Precentral gyrus             −39               3     27    6.25
                                                            L+R   Inferior frontal gyrus       −39               15    −7    6.23
                                                            L+R   Middle frontal gyrus         44                37    20    6.13
                                                            L     Superior frontal gyrus       −28               −9    68    4.33
     Limbic                                                 L+R   Hippocampus†                 57                47    31    5.71
                                                            L     Anterior cingulate           −9                21    19    4.44
     Parietal                                               L     Precuneus                    −28               −76   40    5.94
                                                            L     Inferior parietal lobule     −52               −41   44    5.26
                                                            R     Supramarginal gyrus          42                −45   35    4.34
     Sublobar                                               L+R   Insula                       −37               19    −1    6.14
                                                            L     Caudate                      −5                21    12    4.42
    Diabetic patients                                                                                                        
     Cerebellum                                             L+R   Cerebellum                   −39               −44   −29   7.84
     Frontal                                                L     Medial frontal gyrus         −5                1     58    5.28
                                                            L     Precentral gyrus             −39               1     28    4.73
     Limbic                                                 L+R   Parahippocampal gyrus        −26               −29   −10   5.27
                                                            L+R   Hippocampus†                 58                48    30    4.94
     Sublobar                                               R     Caudate                      14                8     9     5.01
                                                            L     Lentiform nucleus            −24               −5    1     4.89
                                                            L+R   Thalamus                     −26               −31   −1    4.39
    Control \> diabetic patients                                                                                             
     Frontal                                                L     Middle frontal gyrus         −31               47    24    4.34
                                                            L     Inferior frontal gyrus       −46               39    2     3.09
   Deactivation                                                                                                              
    Control                                                                                                                  
     Limbic                                                 L+R   Posterior cingulate cortex   −13               −66   10    5.18
     Occipital                                              L     Cuneus                       −7                −76   16    4.63
                                                            L     Precuneus                    1                 −59   19    4.16
    Diabetic patients                                                                                                        
     Limbic                                                 L     Cingulate gyrus              −11               −56   29    3.59
     Occipital                                              L+R   Cuneus                       0                 −82   20    3.77
     Parietal                                               L+R   Precuneus                    −11               −57   23    3.27
    Diabetic patients (PG \<11 mmol/L) \> (PG ≥11 mmol/L)                                                                    
     Limbic                                                 L+R   Posterior cingulate          16                −66   18    3.94
     Occipital                                              L+R   Cuneus                       −10               −72   18    3.70
  Recognition                                                                                                                
   Activation                                                                                                                
    Control                                                                                                                  
     Cerebellum                                             R     Cerebellum                   35                −62   −28   7.82
     Frontal                                                L     Medial frontal gyrus         −1                12    44    8.07
                                                            L     Inferior frontal gyrus       −39               17    −5    7.75
     Limbic                                                 L+R   Hippocampus†                 31                50    30    6.04
     Parietal                                               L+R   Precuneus                    −32               −69   29    7.09
                                                            L+R   Inferior parietal lobule     −39               −62   41    6.24
                                                            R     Angular gyrus                37                −58   32    5.76
                                                            L     Postcentral gyrus            −24               −35   57    4.74
     Sublobar                                               R     Lentiform nucleus            16                −7    3     8.06
                                                            L     Insula                       −31               22    −1    7.82
     Temporal                                               R     Middle temporal gyrus        33                −66   28    5.23
                                                            R     Superior temporal gyrus      37                −48   26    4.66
    Diabetic patients                                                                                                        
     Cerebellum                                             L+R   Cerebellum                   −22               −85   −26   7.12
     Frontal                                                L     Medial frontal gyrus         1                 12    44    6.80
                                                            L+R   Middle frontal gyrus         37                24    29    4.99
                                                            L     Superior frontal gyrus       −37               54    14    4.87
     Limbic                                                 L+R   Hippocampus†                 31                48    33    5.29
     Parietal                                               L     Precuneus                    −30               −77   36    4.95
                                                            L     Angular gyrus                −39               −62   37    4.35
     Sublobar                                               R     Claustrum                    31                18    1     6.14
     Temporal                                               L     Middle temporal gyrus        −32               −63   28    5.37
   Deactivation                                                                                                              
    Control                                                                                                                  
     Frontal                                                L+R   Medial frontal gyrus         −5                50    3     4.88
     Limbic                                                 L+R   Anterior cingulate           5                 39    −3    5.21
     Temporal                                               L     Middle temporal gyrus        −45               −78   23    5.48
                                                            L     Angular gyrus                −53               −67   31    4.86
                                                            L     Superior temporal gyrus      −62               −61   22    3.42
    Control \> diabetic patients                                                                                             
     Limbic                                                 L+R   Anterior cingulate           5                 34    18    4.29
     Sublobar                                               R     Caudate                      8                 13    −1    4.18
    Diabetic patients (PG \<11 mmol/L) \> (PG ≥11 mmol/L)                                                                    
     Limbic                                                 L     Anterior cingulate           −4                38    −14   3.46
     Frontal                                                L     Superior frontal gyrus       −20               68    −12   3.28
     Frontal                                                L     Medial frontal gyrus         −18               50    −12   3.10
     Frontal                                                L     Middle frontal gyrus         −20               38    −20   2.69

L, left; R, right.

\**z* score for the voxel with the highest level of activation/deactivation or greatest group difference for each region, bilaterally. The threshold for activations and deactivations was *P* \< 0.05 after correction for multiple comparisons using the cluster-based threshold method.

†Results of a hippocampal ROI analysis. Coordinates represent local maxima for the bilateral region of interest.

###### 

Effect of covariates on activation and deactivation during encoding and recognition tasks

                                                                                                 MNI coordinates               
  --------------------------- -------------- ----- ----------- ------- ------------------------- ----------------- ----- ----- ------
  Encoding                                                                                                                     
   APOE4                      Deactivation   CON   Posterior   Right   Cerebellum                25                −66   −19   3.74
                                                   Temporal    Right   Fusiform gyrus            52                −55   −18   4.27
   Lifetime average HbA~1c~   Activation     DM    Frontal     Right   Precentral gyrus          38                −4    26    3.25
                                                   Temporal    Right   Superior temporal gyrus   54                2     −4    2.97
                                                   Sublobar    Right   Insula                    50                10    0     2.89
                                                   Parietal    Right   Postcentral gyrus         58                −4    16    2.79
  Recognition                                                                                                                  
   Current HbA~1c~            Activation     DM    Frontal     Right   Precentral gyrus          50                −16   30    3.24
                                                   Limbic      Right   Cingulate gyrus           12                −30   39    3.09
                                                   Parietal    Right   Postcentral gyrus         39                −24   33    4.22
   HOMA-IR                    Activation     CON   Frontal     Right   Middle frontal gyrus      33                −9    41    4.79
                                                               Right   Precentral gyrus          33                −14   59    3.82
                                                               Right   Inferior frontal gyrus    46                15    12    3.72

Note: only covariates with significant effects are listed. CON, control subjects; DM, type 2 diabetic patients.

\**z* score for the voxel with the highest level of correlation with the covariate for each region. The threshold for correlation was *P* \< 0.05 after correction for multiple comparisons using the cluster-based threshold method.

During both encoding and recognition, we observed bilateral activation of the hippocampus in diabetic patients (mean *z* score ± SD, encoding, left 3.89 ± 0.62, right 3.06 ± 1.13; recognition, left 3.48 ± 0.48, right 3.82 ± 0.93) and control subjects (encoding, left 4.44 ± 0.85, right 4.09 ± 1.16; recognition, left 4.42 ± 0.60 right 4.11 ± 0.68), with no group differences. Local maxima for the hippocampus are listed in [Table 2](#T2){ref-type="table"}.

We observed negative correlations between PG and deactivation in anatomically defined ROIs, including the cuneus (ρ = −0.49, *P* = 0.04) and precuneus (ρ = −0.49, *P* = 0.04) during encoding and the medial frontal gyrus (ρ = −0.52, *P* = 0.03) during recognition.

Discussion {#s15}
==========

This study demonstrates impaired task-induced deactivation in the DMN and aberrant activation in task-relevant regions during a memory task in type 2 diabetic patients. During encoding, we observed reduced activation of task-relevant regions and less extensive deactivation of the DMN in type 2 diabetic patients relative to control subjects. During recognition, we observed impaired deactivation of the DMN in type 2 diabetic patients.

Among diabetic patients, prescan PG levels ≥11 mmol/L were associated with reduced deactivation of DMN regions during both encoding and recognition. There was some overlap between these regions and the regions that differed between diabetic patients and control subjects (e.g., anterior cingulate). We also observed that current HbA~1c~, lifetime average HbA~1c~, and HOMA-IR influence brain activity in the DMN. These observations suggest that several aspects of diabetes, including acute hyperglycemia, short- and long-term glycemic control, and insulin sensitivity, influence DMN activity. Additionally, diabetic patients differed significantly from control subjects on triglycerides and blood pressure. These variables, often comorbid with diabetes, may also contribute to brain differences. Thus, it is possible that the observed abnormalities are related to both metabolic and vascular dysfunction, which are often associated with type 2 diabetes.

The observed brain activity patterns are similar to those found in patients with AD ([@B6]) prior to evident cognitive problems. Recent research has focused on the putative relationship between type 2 diabetes and AD, which may stem from the crucial role that insulin plays in both disorders ([@B16],[@B18]). Glucose metabolism may also be involved ([@B19]); however, the results are not clear ([@B20]). We observed that control subjects who carry the AD risk allele APOE4 showed reduced deactivation in the cerebellum and fusiform gyrus during encoding. Others have found that these regions are recruited during episodic memory tasks ([@B21]), and the cerebellum has previously been shown to be less active in E4 carriers as they age ([@B22]). Differences between our finding and those of others who have observed effects of APOE4 in the medial temporal lobe ([@B23]) may stem from particulars about the memory task and ages of the participants.

This study is cross-sectional; thus, we cannot assert that the observed pattern of functional abnormalities confers increased risk for AD or MCI, although similar abnormalities are seen in populations at risk for AD and in patients with current AD or MCI ([@B6]). There was no evidence of cognitive impairment in this sample; however, significant impairment has often been shown in elderly type 2 diabetic patients ([@B12]), suggesting that the observed fMRI abnormalities may precede cognitive decline. Future studies should use longitudinal designs and evaluate the impact of previous hypoglycemia, exogenous insulin administration, white matter hyperintensities, vascular reactivity, and task vigilance. Exogenous insulin, in particular, has been shown to reduce the BOLD response in a visual task ([@B24]). By incorporating these variables into the design of future studies, we can begin to isolate the etiology of DMN abnormalities in diabetes.

In summary, this study demonstrates that type 2 diabetic patients show hypoactivation of task-relevant regions during encoding and impaired deactivation in the DMN during recognition despite normal cognitive performance, suggesting a reduced ability to modulate task-related brain activity. Acute hyperglycemia, short- and long-term glycemic control, and insulin resistance likely contribute to this abnormality. Through a better understanding of the functional brain abnormalities observed in type 2 diabetes, diagnostic tests and therapies can be developed to detect abnormalities and ameliorate function in vulnerable brain regions, networks, and pathways. Beginning therapies in middle age can help prevent development of clinically significant cognitive impairment.
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